Home › Waldenstrom Macroglobulinemia › North Carolina
Waldenstrom Macroglobulinemia clinical trials in North Carolina
12 studies for Waldenstrom Macroglobulinemia are looking for participants at sites in North Carolina.
Cities in North Carolina
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Southeastern Medical Oncology Center-Clinton, Clinton
- Levine Cancer Institute-Gaston, Gastonia
- and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04840602A Study of ARC-02 in B-cell NHL
- Levine Cancer Institute, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06708897A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- North Carolina Basnight Cancer Hospital, Chapel Hill
Recruiting
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06860880Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- and 4 more
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825Epcoritamab in Previously Treated WM
- University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT06510491Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Duke Univerisity, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT04775745AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.